Non-Consolidated Affiliates (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2023	Jan. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Feb. 11, 2020
Schedule of Equity Method Investments [Line Items]
Equity method investments			$ 350,355		$ 375,894
Equity in (loss) earnings of non-consolidated affiliates			(14,149)	$ 34,606
Distributions from equity method investees			4,965	34,767
Distributions from equity method investees			13,396	16,267
Legacy Investors Partnerships
Schedule of Equity Method Investments [Line Items]
Equity method investments						$ 303,700
Equity in (loss) earnings of non-consolidated affiliates			(9,400)	1,700
Distributions from equity method investees			5,000	2,600
Avillion Entities
Schedule of Equity Method Investments [Line Items]
Equity in (loss) earnings of non-consolidated affiliates			(4,800)	32,900
Equity method investment, unfunded commitments			14,300		$ 16,300
Avillion I
Schedule of Equity Method Investments [Line Items]
Distributions from equity method investees			13,400	$ 13,600
Avillion II
Schedule of Equity Method Investments [Line Items]
Proceeds exercise fee		$ 80,000
Exercise fee, pro rata amount	$ 34,800
Avillion II | Merck Asset - Phase II Clinical Trial
Schedule of Equity Method Investments [Line Items]
Other commitment			$ 155,000